Compare · CSCI vs LLY
CSCI vs LLY
Side-by-side comparison of COSCIENS Biopharma Inc. (CSCI) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSCI and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.14T.
- Over the past year, CSCI is down 29.8% and LLY is up 90.9% - LLY leads by 120.7 points.
- LLY has been more active in the news (15 items in the past 4 weeks vs 1 for CSCI).
- LLY has more recent analyst coverage (25 ratings vs 0 for CSCI).
- Company
- COSCIENS Biopharma Inc.
- Eli Lilly and Company
- Price
- $2.75-10.29%
- $1212.92-1.46%
- Market cap
- -
- $1.14T
- 1M return
- -29.80%
- +2.45%
- 1Y return
- -29.80%
- +90.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 15
- Recent ratings
- 0
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CSCI
- COSCIENS Biopharma Inc. Reports Q2 2026 Results
- COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
- COSCIENS Biopharma Inc. Announces Leadership Change
- COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update
- SEC Form 25 filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
- COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
Latest LLY
- SVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)
- EVP, GC & Secretary Hakim Anat sold $5,950,000 worth of shares (5,000 units at $1,190.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Eli Lilly and Company
- Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
- EVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement